Xilio Therapeutics (XLO) Net Income (2020 - 2026)
Xilio Therapeutics (XLO) posted Net Income of -$14.1 million for Q1 2026, down 19.12% sequentially from -$11.9 million in Q4 2025, and down 1.59% YoY from -$14.4 million in Q1 2025.
Xilio Therapeutics (XLO) Net Income (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Net Income for 7 years, with the latest figure at -$14.1 million in Q1 2026.
- Quarterly Net Income fell 1.59% year-over-year to -$14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.4 million (up 26.35% YoY) and the FY2025 annual result came in at -$167.4 million, up 3.28% from the prior year.
- Net Income retreated to -$14.1 million in Q1 2026 per XLO's latest filing, from -$11.9 million in the prior quarter.
- Over five years, Net Income peaked at -$2.0 million in Q3 2025 and troughed at -$24.8 million in Q2 2022.
- A 5-year average of -$17.0 million and a median of -$17.4 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income slipped 28.13% in 2022, then surged 86.56% in 2025.
- Over 5 years, Net Income stood at -$24.4 million in 2022, then rose by 24.84% to -$18.4 million in 2023, then gained by 24.22% to -$13.9 million in 2024, then rose by 14.72% to -$11.9 million in 2025, then slipped by 19.12% to -$14.1 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$14.1 million, -$11.9 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.62 Mn |
| Mar 31, 2026 | -14.13 Mn |
| Dec 31, 2025 | -11.86 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -14.41 Mn |
| Mar 31, 2025 | -13.91 Mn |
| Dec 31, 2024 | -13.91 Mn |
| Sep 30, 2024 | -14.86 Mn |
| Jun 30, 2024 | -14.88 Mn |
| Mar 31, 2024 | -17.80 Mn |
| Dec 31, 2023 | -18.36 Mn |
| Sep 30, 2023 | -17.40 Mn |
| Jun 30, 2023 | -20.19 Mn |
| Mar 31, 2023 | -23.74 Mn |
| Dec 31, 2022 | -24.42 Mn |
| Sep 30, 2022 | -20.43 Mn |
| Jun 30, 2022 | -24.83 Mn |
| Mar 31, 2022 | -21.42 Mn |
| Dec 31, 2021 | -19.66 Mn |
| Sep 30, 2021 | -31.76 Mn |